Ignite Creation Date:
2024-05-06 @ 7:19 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02511184
Status:
TERMINATED
Last Update Posted:
2019-07-01
First Post:
2015-07-22
Brief Title:
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Sponsor:
Pfizer
Organization:
Pfizer
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10
Start Date Type:
ACTUAL
Primary Completion Date:
2017-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-12
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-22
First Submit QC Date:
July 27 2015
Study First Post Date:
2015-07-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2019-07-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-04
Last Update Post Date:
2019-07-01
Last Update Post Date Type:
ACTUAL